Vertex Pharmaceuticals
Présence
Vertex Pharmaceuticals fait partie des...
Vertex Pharmaceuticals est une société cotée sous le symbole boursier VRTX (US).
Vertex Pharmaceuticals a une présence directe dans 2 pays.
Elles sont en:
- Biotechnologie67%
- Pharmacie33%
Acquisition, funding and merger involving Vertex Pharmaceuticals.
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (publié le 16 avril 2024).
- Vertex Pharmaceuticals has announced the acquisition of ViaCyte (publié le 13 juillet 2022).
Dirigeants
Voir l'organigramme avec ses 65 principaux dirigeants
Biographies les plus recherchées chez Vertex Pharmaceuticals
- Reshma Kewalramani, Director, President and Chief Executive Offic...
- Sangeeta Bhatia, Director
- Jeffrey Leiden, Executive Chairman of the Board
Changements de dirigeants chez Vertex Pharmaceuticals
- Nancy Thornberry, a rejoint l'entreprise comme Director (publié le 6 décembre 2023).
- Michel Lagarde, a rejoint l'entreprise comme Director (publié le 6 octobre 2023).
- Morrey Atkinson qui était Senior Vice Presiden and Head of Commercial Manufacturing & Supply Chain, est promu Executive Vice President, Chief Technical Operations Officer and Head of Biopharmaceutical Sciences & Manufacturing Operations (publié le 30 août 2023).
Créer une alerte
pour suivre les mouvements de dirigeants chez Vertex Pharmaceuticals.
Biotechnologie
Vertex Pharmaceuticals a 2 279 concurrents dont Eurofins (Luxembourg), Lonza (Suisse) et Adaptive Phage Therapeutics (Etats—Unis).
Actualités en fusion/acquisition en Biotechnologie.
- Metsera vient d'annoncer une levée de fonds de 290 millions de dollars. (publié le 23 avril 2024).
- Histogen has filed for bankruptcy protection (publié le 19 avril 2024).
- Bruker has announced the acquisition of NanoString Technologies (publié le 18 avril 2024).
Contacts en Biotechnologie
Actualités
Derniers communiqués de presse par Vertex Pharmaceuticals
- Press Releases | Vertex Pharmaceuticals Newsroom
- Vertex Advances VX-548 in Acute and Neuropathic Pain | Vertex Pharmaceuticals Newsroom
- Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease | Vertex Pharmaceuticals Newsroom
- Vertex to Announce Second Quarter 2022 Financial Results on August 4 | Vertex Pharmaceuticals Newsroom
- Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes | Vertex Pharmaceuticals Newsroom
- Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes | Vertex Pharmaceuticals Newsroom
- Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress | Vertex Newsroom
- Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference | Vertex Newsroom
- Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference on June 15 | Vertex Newsroom
- Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA | Vertex Newsroom
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Vertex Pharmaceuticals
- Vertex Pharmaceuticals sur Wikipédia, Google News & Yahoo Finance en 1-click
- Vertex Pharmaceuticals sur LinkedIn, Twitter & YouTube en 1-click
